Access the Next-Generation of Cancer DiagnosticsOne of the major challenges in diagnosing hematological and solid tumor cancers is the high degree of tumor heterogeneity. Mutations that have critical clinical implications may only be present in very low levels, making detection of these mutations difficult. Detection of such mutations is especially important in hematological and solid tumor malignancies, where tumors show a great deal of heterogeneity and accurate prognosis is essential to identifying patient with more aggressive disease. Next-generation sequencing (NGS) helps respond to these challenges by providing a comprehensive view of the tumor’s genomic profile. Importantly, NGS can detect multiple mutations present at very low levels within the tumor.
Targeted NGS Panels for Solid Tumors
Solid Tumors NGS Panel is designed to cover hotspot mutations of 35 unique genes in various different types of solid tumors including but not limited to lung cancer, colorectal cancer, skin cancer, breast cancer, bladder cancer, and thyroid cancer. The assay utilizes sequencing of DNA targets allowing detection of 989 hotspot variants, including single nucleotide variants (SNVs), with a very low input DNA material. The assay is designed to detect hotspot mutations that have clinical utility in prognosis or diagnosis or therapeutic implications in various solid tumors. The biomarkers included in the Solid Tumor NGS Panel were selected based on information in the Oncomine Knowledgebase and confirmed with industry-leading pharmaceutical partners. The results of the assay should be interpreted in the context of available clinical, pathologic, and laboratory information.
Gene List for Mutation Detection (35)
AKT1, ALK, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO.